Last reviewed · How we verify

ADX-038 — Competitive Intelligence Brief

ADX-038 (ADX-038) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PI3K delta and gamma inhibitor. Area: Immunology.

phase 2 PI3K delta and gamma inhibitor PI3K delta and gamma Immunology Small molecule Live · refreshed every 30 min

Target snapshot

ADX-038 (ADX-038) — ADARx Pharmaceuticals, Inc.. ADX-038 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ADX-038 TARGET ADX-038 ADARx Pharmaceuticals, Inc. phase 2 PI3K delta and gamma inhibitor PI3K delta and gamma

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PI3K delta and gamma inhibitor class)

  1. ADARx Pharmaceuticals, Inc. · 2 drugs in this class
  2. Astellas Pharma Europe B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ADX-038 — Competitive Intelligence Brief. https://druglandscape.com/ci/adx-038. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: